China Resources Shuanghe: Wholly-owned subsidiary DC6001 receives FDA Investigational New Drug (IND) approval for clinical trials.

China Resources Double Crane announced that the clinical trial application for the new drug DC6001 submitted by its wholly-owned subsidiary Shuanghe Runchuang to the FDA has taken effect and has entered the stage of clinical trial advancement. The indication of this drug is Stargardt's disease, which had previously received approval for clinical trials from the National Medical Products Administration. Shuanghe Runchuang submitted the IND application on November 26, 2025, and received the confirmation letter on December 9, indicating that the permit period has expired. In addition, the drug has received FDA designation as a rare pediatric disease drug. As of the announcement date, the company has accumulated research and development investment of 17.36 million yuan for this drug. However, the drug is still in the early stages of clinical development and there is uncertainty regarding its commercialization.